Toxicology Letters
October 8, 2009
Markus R Meyer, Frank T. Peters, Hans H Maurer
3,4-Methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) are chiral designer drugs distributed on the illicit drug market and they are also N-dealkyl metabolites of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Adam), 3,4-methylenedioxyethylamphetamine (MDEA, Eve), and N-methyl-benzodioxolyl-butanamine (MBDB, Eden), respectively. MDA and BDB are mainly metabolized via...
Drug metabolism and disposition: the biological fate of chemicals
October 2009
Melanie Mueller, Jie Yuan, Anne Felim et al.
The mechanism by which the recreational drug (+/-)-3,4-methylenedioxymethamphetamine (MDMA) destroys brain serotonin (5-HT) axon terminals is not understood. Recent studies have implicated MDMA metabolites, but their precise role remains unclear. To further evaluate the relative importance of metabolites versus the parent compound in neurotoxicity, we explored the relationship between...
Therapeutic Drug Monitoring
June 1, 2009
Melanie Mueller, Erin A Kolbrich, Frank T. Peters et al.
The present study compared the disposition and metabolism of the recreational drug (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) in squirrel monkeys and humans because the squirrel monkey has been extensively studied for MDMA neurotoxicity. A newly developed liquid chromatography-mass spectrometric procedure for simultaneous measurement of MDMA, 3,4-dihydroxymethamphetamine,...
Biochemical Pharmacology
June 1, 2009
Markus R Meyer, Frank T. Peters, Hans H Maurer
In the present study, cytochrome P450 isozymes (P450) involved in the stereoselective metabolism of the designer drug N-methyl-benzodioxolyl-butanamine (MBDB, Eden) were identified for the first time. Demethylenation and N-demethylation of racemic MBDB as well as its single enantiomers were investigated using cDNA-expressed insect cell microsomes. After incubation of MBDB, the two resulting...
Clinical Chemistry
March 2, 2007
Frank T. Peters, Nele Samyn, Thomas Kræmer et al.
36 citations
Abstract Background: Enantioselective analysis of amphetamine (AM), methamphetamine (MA), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) helps interpret toxicological results. Methods have been described for various matrices, but so far not for oral fluid, a matrix of increasing importance in testing for drugs of...
Clinical Chemistry
August 11, 2005
Frank T. Peters, Nele Samyn, C. T. J. Lamers et al.
49 citations
Abstract Background: The enantiomers of the designer drugs 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) differ in their pharmacologic and toxicologic potency. The aim of this study was to develop an assay for measuring these enantiomers in small plasma volumes and to analyze samples from a controlled study with...
Journal of mass spectrometry : JMS
June 1, 2005
Vilma Habrdova, Frank T. Peters, Denis S Theobald et al.
61 citations
In recent years, several newer designer drugs of the so-called 2C series such as 2C-D, 2C-E, 2C-P, 2C-B, 2C-I, 2C-T-2, and 2C-T-7 have entered the illicit drug market as recreational drugs. Some fatal intoxications involving 2C-T-7 have been reported. Only scarce data have been published about analyses of these substances in human blood and/or plasma. This paper describes a method for screening...
Journal of Analytical Toxicology
November 1, 2003
Frank T. Peters, Nele Samyn, Martin Wahl et al.
65 citations
Enantiomers of amphetamine (AM), methamphetamine (MA), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) exhibit different pharmacological properties. This may be important for the interpretation of analytical results. Plasma samples were analyzed using validated negative ion chemical ionization gas chromatography-mass...
Journal of Mass Spectrometry
June 1, 2003
Frank T. Peters, Simone Schaëfer, Roland F. Staack et al.
171 citations
Abstract The classical stimulants amphetamine, methamphetamine, ethylamphetamine and the amphetamine‐derived designer drugs MDA, MDMA (‘ecstasy’), MDEA, BDB and MBDB have been widely abused for a relatively long time. In recent years, a number of newer designer drugs have entered the illicit drug market. 4‐Methylthioamphetamine (MTA), p ‐methoxyamphetamine (PMA) and p ‐methoxymethamphetamine...